Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhao Y, Kishi T, Iwata N, Ikeda M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/1df274f946db4807bad1c0676f92fe23
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1df274f946db4807bad1c0676f92fe23
record_format	dspace
spelling	oai:doaj.org-article:1df274f946db4807bad1c0676f92fe232021-12-02T04:51:06ZCombination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia1176-63281178-2021https://doaj.org/article/1df274f946db4807bad1c0676f92fe232013-10-01T00:00:00Zhttp://www.dovepress.com/combination-treatment-with-risperidone-long-acting-injection-and-psych-a14815https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan; 4Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan Abstract: A recent meta-analysis showed that long-acting injectable (LAI) antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set), an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy). Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS) and Global Assessment of Functioning (GAF) scores. Of the 96 patients originally enrolled, 19 (19.8%) were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4%) relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total scores (P = 0.0031), BPRS positive (P = 0.0451), BRPS negative (P < 0.0001), and general subscale scores (P = 0.0031), and GAF (P < 0.0001) from baseline to 6 months. In conclusion, the lower relapse rate observed in patients treated with COMPASS plus risperidone LAI than in patients treated with risperidone LAI alone suggests that COMPASS may have benefits in the treatment of schizophrenia, indicating a need for randomized, controlled trials in larger numbers of patients. Keywords: adherence, risperidone long-acting injection, psychoeducation, schizophreniaZhao YKishi TIwata NIkeda MDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1655-1659 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Zhao Y Kishi T Iwata N Ikeda M Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
description	Yueren Zhao,1–3 Taro Kishi,1 Nakao Iwata,1 Manabu Ikeda3,4 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; 2Department of Psychiatry, Okehazama Hospital Fujita Kokoro Care Center, Toyoake, Aichi, Japan; 3Department of Neuropsychiatry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan; 4Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan Abstract: A recent meta-analysis showed that long-acting injectable (LAI) antipsychotics were not superior to oral antipsychotics for preventing relapse in patients with schizophrenia. We therefore designed a treatment strategy combining risperidone LAI and COMPASS (COMprehensive Psycho-educational Approach and Scheme Set), an original psychoeducational program supporting treatment with risperidone LAI and evaluating subjective treatment satisfaction, transition of symptoms, and effectiveness in preventing symptomatic relapse. The aim of this study was to examine whether addition of COMPASS to risperidone LAI was more effective in preventing relapse in schizophrenia patients than risperidone LAI alone, with the latter group consisting of patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients were followed up for 6 months, with COMPASS continuously implemented from the transition to the observation phase. The primary efficacy measurements were relapse rate (rates of rehospitalization and discontinuation due to inefficacy). Secondary efficacy measurements were the Brief Psychiatric Rating Scale (BPRS) and Global Assessment of Functioning (GAF) scores. Of the 96 patients originally enrolled, 19 (19.8%) were discontinued from all causes. During the 6-month study period, ten of the 96 patients (10.4%) relapsed, compared with a 12.2% relapse rate in patients enrolled in a Phase III trial of risperidone LAI in Japan. Patients showed significant improvements in BPRS total scores (P = 0.0031), BPRS positive (P = 0.0451), BRPS negative (P < 0.0001), and general subscale scores (P = 0.0031), and GAF (P < 0.0001) from baseline to 6 months. In conclusion, the lower relapse rate observed in patients treated with COMPASS plus risperidone LAI than in patients treated with risperidone LAI alone suggests that COMPASS may have benefits in the treatment of schizophrenia, indicating a need for randomized, controlled trials in larger numbers of patients. Keywords: adherence, risperidone long-acting injection, psychoeducation, schizophrenia
format	article
author	Zhao Y Kishi T Iwata N Ikeda M
author_facet	Zhao Y Kishi T Iwata N Ikeda M
author_sort	Zhao Y
title	Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
title_short	Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
title_full	Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
title_fullStr	Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
title_full_unstemmed	Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
title_sort	combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/1df274f946db4807bad1c0676f92fe23
work_keys_str_mv	AT zhaoy combinationtreatmentwithrisperidonelongactinginjectionandpsychoeducationalapproachesforpreventingrelapseinschizophrenia AT kishit combinationtreatmentwithrisperidonelongactinginjectionandpsychoeducationalapproachesforpreventingrelapseinschizophrenia AT iwatan combinationtreatmentwithrisperidonelongactinginjectionandpsychoeducationalapproachesforpreventingrelapseinschizophrenia AT ikedam combinationtreatmentwithrisperidonelongactinginjectionandpsychoeducationalapproachesforpreventingrelapseinschizophrenia
_version_	1718400995378069504

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia

Ejemplares similares